8 minutes | Thursday, July 6, 2023
The US Food and Drug Administration is expected to decide whether to grant traditional approval to the Alzheimer’s drug Leqembi, the first medicine proven to slow the course of the memory-robbing disease. An approval decision would also be expected to trigger a change in how the Centers for Medicare and Medicaid Services covers the drug, broadening access for up to an estimated million people with early forms of the disease. Ed examines what this may mean to millions of people.